Clinical Trial Update: Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating whether eplerenone can reduce recurrence of atrial fibrillation in patients with structural heart disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Inspra (Eplerenone) (Eplerenone)

Snippet

Sponsor: Assiut University | Conditions: Atrial Fibrillation | Phase 1 | Status: RECRUITING